Tannic Acid Inhibits CaMKII-β Kinase Activity In Vitro and Displays Preclinical Anti-Tumor Activity in Ovarian Cancer Models
Year: 2026
Type: article
Abstract: Ovarian cancer (OC) is characterized by delayed clinical diagnosis, intrinsic/acquired platinum chemoresistance, and a high postoperative recurrence rate, highlighting an unmet clinical need for new targeted therapeutic strategies. Herein, we integrated pan-cancer transcriptomic profiling, clinical tissue immunohistochemistry, siRNA-mediated gene silencing, co-immunoprecipitation, structure-based virtual ligand screening, in vitro kinase activity assays, cellular viability functional assays, and SK-OV-3 xenograft mouse models to preliminarily reveal that CaMKII-β may mediate OC progression and characterize the anti-tumor potency of tannic acid. We preliminarily found that CaMKII-β is upregulated in OC patient tissues, and its elevated expression correlates with unfavorable overall survival. Genetic depletion of CaMKII-β attenuated OC cell viability both in vitro and in vivo via interfering with RAS-related signaling and suppressing downstream PI3K, AKT, and NF-κB transcriptional signaling cascades. Structure-based virtual screening identified tannic acid as a candidate CaMKII-β inhibitor with an IC50 value of 217 nM. Functional cellular assays demonstrated that tannic acid suppresses OC cell viability in a dose-dependent manner, accompanied by reduced phosphorylation of PI3K, AKT, and NF-κB, while the total protein levels of these signaling intermediates remain unaltered. In vivo intraperitoneal injection of tannic acid impeded the growth of SK-OV-3 xenograft tumors without inducing measurable systemic weight loss in host mice. In summary, CaMKII-β may contribute to malignant progression of OC through its association with RAS-related signaling, and tannic acid shows pre-clinical preliminary anti-tumor activity associated with CaMKII-β-related signaling in OC. Further mechanistic validation, pharmacokinetic, toxicological, and clinically relevant in vivo studies are required to evaluate its translational potential.
Source: Cells
Institutions: Taiyuan University of Technology, Shanxi Medical University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,258
Funder: Taiyuan University of Technology
OpenAlex ID: W7225920616
